Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis

Passero, Luiz Felipe Domingues; Carvalho, Ana Kely; Bordon, Maria L. A. C.; Bonfim-Melo, Alexis; Toyama, Marcos H.; Corbett, Carlos Eduardo Pereira; Laurenti, Márcia Dalastra

doi:10.1007/s00011-011-0407-5

Cited by 3 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of this study provide a warning for the possible association between L. (V.) shawi and mucous lesions, since L. (V.) braziliensis can be found both in normal mucosa and in injured mucosa [5]. Experimental studies showed that infection by L. (V.) shawi without symptoms in mice can occur through the activation of antigens capable of inducing a protective immune profile, which is important for the development of vaccines against TL [34,35]. These observations allow for further studies in the fields of genomics and bioinformatics in this species of Leishmania.…”

Section: Discussionmentioning

confidence: 77%

First Report of an Asymptomatic Leishmania (Viannia) shawi Infection Using a Nasal Swab in Amazon, Brazil

Oliveira

Nascimento

Santos

et al. 2022

IJERPH

View full text Add to dashboard Cite

The state of Pará has recorded seven Leishmania species that cause tegumentary leishmaniasis (TL). Leishmania species induce distinct immunological responses from the host and exhibit resistance to Glucantime, the first-line drug treatment for TL in Brazil. Objective: Identify the etiology of TL in an Amazonian city in the state of Pará. Material and methods: Eleven patients with TL were recruited and nasal swabs, lesion swabs, and skin fragments samples were collected. In the control group (n = 6), only the nasal swabs were collected. Polymerase Chain Reaction (PCR) amplification of the gene region hsp70-234 was performed using the extracted DNA from the samples, from which nine patients with TL and five in the control group were positive. Products were sequenced, mounted in CAP3 software, aligned using MAFFT v.7.221, edited in Geneious software v.8.1.7, and compared and aligned with sequences available in GenBank using the BLAST tool. Results: For patients with TL, six molecular diagnosis at the species level (L. (Viannia) braziliensis (n = 5/9), L. (Viannia) shawi (n = 1/9)) and three at the genus level (Leishmania sp. (n = 3/9)) were obtained. In the control group, four individuals were infected with Leishmania sp. (n = 4/5) and L. (V.) shawi (n = 1/5). Conclusion: This is the first report of L. (V.) shawi infection in the mucosal secretion of a healthy person in Brazil. Moreover, genetic variants were identified in the haplotypes of L. (V.) braziliensis in the gene sequence hsp70-234.

show abstract

Section: Discussionmentioning

confidence: 77%

First Report of an Asymptomatic Leishmania (Viannia) shawi Infection Using a Nasal Swab in Amazon, Brazil

Oliveira

Nascimento

Santos

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

Treatment with triterpenic fraction purified from Baccharis uncinella leaves inhibits Leishmania (Leishmania) amazonensis spreading and improves Th1 immune response in infected mice

et al. 2013

View full text Add to dashboard Cite

The current medications used to treat leishmaniasis have many side effects for patients; in addition, some cases of the disease are refractory to treatment. Therefore, the search for new leishmanicidal compounds is indispensable. Recently, it was demonstrated that oleanolic- and ursolic-containing fraction from Baccharis uncinella leaves eliminated the promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and L. (Viannia) braziliensis without causing toxic effects for J774 macrophages. Thus, the aim of the present work was to characterize the therapeutic effect of the triterpenic fraction in L. (L.) amazonensis-infected BALB/c mice. Oleanolic- and ursolic acid-containing fraction was extracted from B. uncinella leaves using organic solvents and chromatographic procedures. L. (L.) amazonensis-infected BALB/c mice were treated intraperitoneally with triterpenic fraction during five consecutive days with 1.0 and 5.0 mg/kg of triterpenic fraction, or with 10.0 mg/kg of amphotericin B drug. Groups of mice treated with the triterpenic fraction, presented with decreased lesion size and low parasitism of the skin-both of which were associated with high amounts of interleukin-12 and interferon gamma. The curative effect of this fraction was similar to amphotericin B-treated mice; however, the final dose, required to eliminate amastigotes, was lesser than amphotericin B. Moreover, triterpenic fraction did not cause microscopic alterations in liver, spleen, heart, lung, and kidney of experimental groups. This work suggests that this fraction possesses compounds that are characterized by leishmanicidal and immunomodulatory activities. From this perspective, the triterpenic fraction can be explored as a new therapeutic agent for use against American Tegumentar Leishmaniasis.

show abstract

Plants Used in Traditional Medicine: Extracts and Secondary Metabolites Exhibiting Antileishmanial Activity

Passero

Laurenti

Santos‐Gomes³

et al. 2014

CCP

View full text Add to dashboard Cite

Leishmania (Viannia) shawi purified antigens confer protection against murine cutaneous leishmaniasis

Abstract: The capability of antigens to restrain IL-4 levels and increase IFN-γ was associated with protection, such as in immunization using F1 antigen.

Cited by 3 publications

References 52 publications

First Report of an Asymptomatic Leishmania (Viannia) shawi Infection Using a Nasal Swab in Amazon, Brazil

First Report of an Asymptomatic Leishmania (Viannia) shawi Infection Using a Nasal Swab in Amazon, Brazil

Treatment with triterpenic fraction purified from Baccharis uncinella leaves inhibits Leishmania (Leishmania) amazonensis spreading and improves Th1 immune response in infected mice

Plants Used in Traditional Medicine: Extracts and Secondary Metabolites Exhibiting Antileishmanial Activity

Contact Info

Product

Resources

About